Emcure Pharmaceuticals is locked its upper circuit at Rs. 1288.65, up by 117.15 points or 10.00% from its previous closing of Rs. 1171.50 on the BSE.
The scrip opened at Rs. 1202.10 and has touched a high and low of Rs. 1288.65 and Rs. 1202.10 respectively. So far 22398 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1577.50 on 18-Sep-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1288.65 and Rs. 1046.80 respectively. The current market cap of the company is Rs. 24417.77 crore.
The promoters holding in the company stood at 77.92%, while Institutions and Non-Institutions held 6.51% and 15.57% respectively.
Emcure Pharmaceuticals has received approval for incorporation of a wholly-owned subsidiary (WOS) by the name ‘Emcure Generics’ in Pune, Maharashtra, India. The WOS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
The Board of Directors of the company in their meeting held May 22, 2025, has approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: